Risk of Heart Failure Hospitalization Associated With Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis-Stimulating Agents: A Nationwide Claims-Based Cohort Study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Association of Heart Failure Hospitalization Risk with Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Compared to Erythropoiesis-Stimulating Agents: A Nationwide Claims Analysis

  • By

  • Yuki Kunitsu

  • Keiko Ikuta

  • Daiki Hira

  • Shunsaku Nakagawa

  • Tomohiro Terada

  • August 29, 2026

Share

  • 1

    HIF-PHIs are oral therapies for renal anemia that stabilize HIF pathways and stimulate erythropoietin production.

  • 2

    Daprodustat, a HIF-PHI, is associated with an increased risk of heart failure hospitalization compared to ESAs in non-dialysis CKD patients.

  • 3

    The study utilized a nationwide Japanese claims database to assess heart failure hospitalization risk associated with HIF-PHIs.

  • 4

    Patients with heart failure were included if they initiated HIF-PHIs or ESAs while receiving ongoing diuretic therapy.

  • 5

    The primary outcome measured was hospitalization for heart failure, with secondary outcomes including emergency hospitalization and intravenous diuretic administration.

Original Source(s)

Risk of Heart Failure Hospitalization Associated With Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis-Stimulating Agents: A Nationwide Claims-Based Cohort Study

  • by Yuki Kunitsu, Keiko Ikuta, Daiki Hira, Shunsaku Nakagawa, Tomohiro Terada

  • August 29, 2026

Related Content

Linear dose-response relationship between TyG-WC index and diastolic dysfunction: insights from restricted cubic spline and machine learning analysis

Efficacy and safety of quadruple therapy versus triple therapy in patients with heart failure with preserved ejection fraction: a propensity score-matched real-world study

Development and validation of a clinical prediction model for sepsis-induced cardiomyopathy